iTeos Therapeutics price target lowered to $21 from $46 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on iTeos Therapeutics (ITOS) to $21 from $46 and keeps a Buy rating on the shares. The firm removed expected revenue from inupadenant in lung cancer following the interim data.